



August, 2019

EVOGENE AT A GLANCE...

Ofer Haviv,
President & CEO



SAFE HARBOR STATEMENT

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

AGENDA

What we
do...

Our
technology -
the CPB
platform

Target
markets

Corporate
structure &
activities

Summary

Annex I:
subsidiary
overview

Annex II:
financial
fundamentals

WHAT WE DO...

We revolutionize the product development process in life-science based markets...

...through the use of a unique Computational Predictive Biology (CPB) platform



AGENDA

What we
do...

Our
technology -
the CPB
platform

Target
markets

Corporate
structure &
activities


Summary

Annex I:
subsidiary
overview

Annex II:
financial
fundamentals

THE CHALLENGE

Product development common practice



Low probability of success


Long time to market

High development costs


Limited 'next generation' products in pipelines

THE DESIRED SOLUTION


Candidates with the highest probability of success



EVOGENE'S UNIQUE PRODUCT DEVELOPMENT APPROACH



The CPB platform



Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at **Stage Zero**

PREDICTION OF CANDIDATES FOR LIFE-SCIENCE BASED PRODUCTS



CPB
platform



Genetic
Elements



Small
Molecules



Microbes



ATHLETE™

Plant genes – associated to specific plant traits



GEDAI

Plant edits – edits to control gene expression



EvoBreed™

Genomic markers – genomics tools to assist breeders*



BiomeMiner™

Bacterial genes – toxins for insects



PoinTar™

Essential genes – target for herbicides



PointHit™

Small chemical molecules – associated to targeted proteins



PointLead™

Optimized small chemical molecule – improved commercial viability



MicrobeMiner

Plant microbes – associated to specific plant traits



Prism

Human microbes – associated with human diseases

AGENDA

What we
do...

Our
technology -
the CPB
platform

Target
markets

Corporate
structure &
activities

Summary

Annex I:
subsidiary
overview


Annex II:
financial
fundamentals

TARGETED MARKETS

Biotechnology for life science industries

Green - Agriculture

- Ag-Chemicals
- Seeds
- Ag-Biologicals
- Precision Ag
- Livestock
- Biomaterials
- Energy



White- Industrial

- Industrial application
- Polymers
- Enzymes
- Bacteria

Red - Human Health

- Medical Cannabis
- Pharmaceutical industry
- Medical application
- Diagnostics

Blue - Aquamarine

- Aquaculture
- Health

AGENDA

What we
do...

Our
technology -
the CPB
platform

Target
markets


Corporate
structure &
activities

Summary

Annex I:
subsidiary
overview

Annex II:
financial
fundamentals

CORPORATE STRUCTURE & ACTIVITIES




**Corteva Agriscience to Invest in Evogene's
Agriculture Biologicals Subsidiary, Lavie Bio**

***Investment Includes Equity and Corteva's
Shares in Taxon Biosciences for Shares in Lavie Bio***

Wilmington, Del., USA and Rehovot, Israel – Aug. 7, 2019 – Corteva, Inc. (NYSE: CTVA), a leading pure-play agriculture company, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Corteva will make an investment in Evogene's agriculture biologicals subsidiary, Lavie Bio (Lavie). The transaction includes the exchange of all shares of Corteva's wholly owned subsidiary Taxon Biosciences along with an equity investment by Corteva in Lavie. As consideration for the Taxon Biosciences shares and equity investment, Corteva will be issued approximately 30 percent of Lavie's equity while Evogene will hold approximately 70 percent of Lavie's equity.

Taxon Biosciences' capabilities are expected to provide significant synergetic value to Lavie and accelerate the development of Lavie's products. Taxon Biosciences' assets, including a large microbial collection and product candidate pipeline, will be integrated into Lavie's pipeline, accelerating Lavie's '*biology driven design*' approach and its product development.

MAIN COLLABORATIONS



MILESTONE ROADMAP



Enter new collaboration agreement



Complete first pre-clinical study in oncology



Complete two cannabis growth cycles



Complete semi-commercial field trials



Advance product pipeline in wheat bio-stimulants



Achieve non-regulated approval for genome-edited soybean products for nematodes



Achieve commercial efficacy level, in-vitro, for at least one toxin

2019



Reach 'Lead' in herbicide program



Enter pre-clinical trials in 2 additional programs; positive results in at least one study



Demonstrate first desired cannabis trait



Enter commercial scale field trials



Complete semi-commercial trials toward 2022 commercialization



Achieve genome-edited soybean lines for nematode resistance



Positive results in soybean/corn for insect control trait

2020

AGENDA

What we
do...

Our
technology -
the CPB
platform

Target
markets

Corporate
structure &
activities

Summary

Annex I:
subsidiary
overview

Annex II:
financial
fundamentals

EVOGENE AT A GLANCE... SUMMARY

WHAT WE DO

We revolutionize the product development process in life-science based markets through the use of a unique Computational Predictive Biology (CPB) platform.

OUR TECHNOLOGY – THE CPB PLATFORM

Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at 'Stage Zero'.

CPB CAPABILITIES FOR PREDICTION OF INNOVATION

- Genetic elements – controlling desired biological processes
- Small molecules – active ingredients for chemical based products
- Microbes – active ingredients for microbial based products

TARGET MARKETS AND CURRENT ACTIVITIES

- Agriculture - Ag-Chemicals, Seed Traits, Ag-Biologicals
- Human Health – Human Microbiome, Drug Discovery, Medical Cannabis
- Industrial Applications – Castor oil

MAIN COLLABORATIONS WITH WORLD-LEADING COMPANIES



CORPORATE STRUCTURE

Evogene and the CPB platform at the heart of a group of subsidiaries, each focused in different life-science based markets, with exclusive access to the CPB platform for their field of activity, providing their main competitive advantage for their product development pipeline.

FINANCIAL FUNDAMENTALS

- Cash position - \$ 46 M (June 30, 2019), no debt
- Listed on TASE (2007) and NASDAQ (2013)



August, 2019

EVOGENE AT A GLANCE...

Ofer Haviv,
President & CEO

Contact:


ir@evogene.com

T: +972 8 931 1963



Annex I: Subsidiary Overview

CORPORATE STRUCTURE



AGPLENUS (AG-CHEMICALS)

MISSION & PRODUCTS

MISSION

Design effective and sustainable crop protection products
by leveraging predictive biology

Main Products under development




Herbicides –Market size: \$25B* (2018), growing market need for novel herbicides with improved safety profile and solution for increasing resistance to current herbicides



Insecticides - Market size: \$15B* (2018), growing market need for improved insecticide selectivity and solution for increasing resistance to current insecticides


BUSINESS MODEL

Delivering de-risked lead candidates



Delivering de-risked Lead candidates targeting large multinational agrochemical companies

AGPLENUS (AG-CHEMICALS) - PIPELINE



Ongoing collaborations – vote of confidence from leading Ag players




Novel herbicides - new mode of action (2016)

Novel insecticides - new site of action (2018)



Novel crop enhancers development (2017)

CORPORATE STRUCTURE



LAVIE BIO (AG-BIOLOGICALS)

MISSION & PRODUCTS

MISSION

Improve food quality, health and sustainability through the introduction of microbiome based ag-biologicals products

Products under development:



Bio-Stimulant – Market size: \$2B* (2016), Microbial based targeting yield improvement in row crops such as corn, wheat





Bio-Pesticides (Bio-Insecticides & Bio-Fungicides) - Market size: \$1.2B* (2016), Microbial based treatments, targeting insects (corn rootworm, stinkbug and lepidoptera) and fungi (fusarium and mildew)



Bio X – Microbial based consumer trait products

BUSINESS MODEL



Model A – Direct Market Access

Model B – Market Access via partner




Co-development of corn bio-stimulants with Corteva

LAVIE BIO (AG-BIOLOGICALS) - PIPELINE

Product program		Application	Discovery	Early Dev.	Dev.stage 1	Dev. stage 2	Commerciali zation	Product
<u>Bio Stimulants</u>								
Corn		Yield improvement under normal & drought	Seed treatment					
Wheat		Yield improvement under normal & drought	Seed treatment					
<u>Bio Pesticides</u>								
Fusarium and seedlings disease (Corn)		Protect from Fusarium, other soil diseases and mycotoxins	Seed treatment					
Mildew, Fruit rot (focus on Grapes)		Protect from mildews and reduce chemical load	Foliar					
<u>Bio X</u>								
Consumer trait A		Add consumer trait P1, P2	Foliar ,seed treatment					

CORPORATE STRUCTURE



AG SEEDS - MISSION & PRODUCTS

MISSION

Bring to market top-quality seeds with high-value traits, under the “Triple S”
Concept – Safe, Secure and Sustainable food

Products under development mainly via (i) GMO and (ii) Genome Editing :



Insect control traits- Lepidoptera, Coleoptera, Hemiptera



Yield and environmental stress traits- Yield, drought, nitrogen usage efficiency




Disease resistance traits- Fusarium, Black Sigatoka, Asian Rust, Nematodes

- (i) **GMO** - genetically modified organism: an organism whose genetic material has been altered by means of genetic engineering
- (ii) **Genome Editing** - edits made to the existing genome

INSECT CONTROL


Discover & develop novel proteins conferring resistance to key insects through new modes of action



Diverse trait portfolio with novel Mode of Action !


INSECT CONTROL- EXAMPLE

Confirmed protection from Southern Green Stinkbug (STK) in transgenic tomato in 3 experiments



- STK is a major Cotton & Soybean pest
- No trait solution in the market
- EV040030208 is a member of a gene family, 1st hit in a potential 'gold mine' of additional novel insecticidal genes


YIELD AND ENVIRONMENTAL STRESS PRODUCT CANDIDATES*



YIELD AND ENVIRONMENTAL STRESS COLLABORATION EXAMPLE BAYER (MONSANTO)


- **Collaboration period** - 10 years
- **Objective** - improved seeds via biotechnology
- **Crops** - corn, soybean, cotton, canola
- **Traits** - (i) Yield/drought tolerance/fertilizer utilization
(II) Fusarium resistance in corn

- **Key terms** -
- R&D and up-front payments - total ~\$68M
- Milestone payments + royalties from sales
- \$30M equity investment




DISEASE RESISTANCE PRODUCT CANDIDATES*

Disease Resistance GMO Product Candidates:*



Genome Editing Disease Resistance Product Candidates:



GENOME EDITING DISEASE RESISTANCE EXAMPLE




Evogene Amends its Collaboration Agreement with Bayer to Include Genome Editing Targets

Amended agreement follows positive results in corn stalk rot fungal disease control

Rehovot, Israel – July 16, 2019 - Evogene Ltd. (NASDAQ, TASE: EVGN) a leading biotechnology company developing novel products for life science markets, announces today that after achieving positive results, its corn disease resistance research collaboration with the Crop Science Division of Bayer¹ is being refocused on the identification of genome editing targets for evaluation against a broad range of corn diseases. Evogene will use its CPB (Computational Predictive Biology) platform to identify the required edits to improve disease resistance in corn. The edits will be based on Evogene-discovered genes and the accumulated knowledge achieved through this collaboration, focusing on altering gene expression or function. Any promising targets would be pursued by Bayer's in-house team for validation.

CORPORATE STRUCTURE



BIOMICA – MISSION & PRODUCTS

MISSION

Discovery and development of novel therapies
for microbiome-related human disorders using computational predictive biology

Products under development:

Microbiome and small molecule based therapies for:

- Immuno-oncology (with ICI) – combination therapy for cancer
- MDRO (Multi Drug resistant organisms) – targeting antibiotic resistant bacteria
- GI related disorders - GI inflammatory & functional disorders

BIG BIOPHARMA IS INVESTING MORE THROUGH PARTNERSHIPS



Obesity and
metabolic disease
2014



Inflammatory
bowel disease
2013



Ulcerative
Colitis
2013



Crohn's
disease
2016



Inflammatory
bowel disease
2016



Inflammatory
bowel disease
2017



Gastrointestinal
indications
2017



Crohn's
disease
2014



Inflammatory
bowel disease
2016



Inflammatory
bowel disease
2017



Immunooncology
2016



Immunooncology
2018



Inflammatory
bowel disease



2018



Obesity and
diabetes

2018



C. Ddiff, inflam,
bowel disease

2016



Diagnostics

2017

PIPELINE

	Program	Indication / Target	Discovery	Preclinical	Phase 1	Phase 2	Approach
Immuno-oncology (with ICI)	BMC121	Combination Therapy for NSCLC					
	BMC127	Combination Therapy for NSCLC					
MDRO	BMC201	C. difficile toxin-B					
GI related disorders	BMC426	IBS					
	BMC321	IBD					
	BMC322	IBD					




Biological



Small Molecule

CORPORATE STRUCTURE



CANONIC

MISSION & PRODUCTS


MISSION

To develop and bring to market
medical grade cannabis through a revolutionary genomic approach

Products under development:

- MetaYield* - Increased metabolite yield
- Unican* - Verified variety stability
- Precise* - Tailored metabolite profiles targeting:
 - Chronic pain
 - PTSD – Post traumatic stress disorder
 - Cancer care

Innovative products to address key market needs:



BUSINESS MODEL

Canonic aims to develop elite cannabis varieties for commercialization of medical products directly or via partnerships

CANONIC

Potential partnerships

Varieties dev.

Unique
varieties

Seed production

Seeds

Cannabis growth

Flowers

Formulation

Clinical
validation &
regulation

MILESTONE ROADMAP

2019

- Establishment of R&D growing facility
- Complete two cannabis growth cycles
- Establish agronomic protocols
- Build cannabis core collection
- Establish initial cannabis database



2020

- First product trait demonstrated
- Complete three cannabis growth cycles
- Complete establishment of proprietary cannabis database
- Expand core collection of cannabis varieties




2021

- Finalize development of first improved variety
- Pre-commercial stage
- Seed increase to allow production
- Finalize formulation process



CORPORATE STRUCTURE



CASTERRA MISSION & PRODUCTS

MISSION

Providing stable supply for the growing market demand for castor oil

Product:

An integrated ag-solution for castor - **proprietary castor seed varieties** supported by **novel agro-technical know-how** and **proprietary mechanical harvesting**.

Current Practice:

Common castor family size, tall shrub, hand-picked



- Traditional cultivation
- Low yield (0.6 MT/Ha.)
- Manual harvest

Casterra solution:

Modern row-crop cultivation




- Compact plants, high density
- High oil content
- Adapted to commercial mechanical harvest

casterra



BUSINESS MODEL AND TECHNOLOGICAL POSITION

Revenue sharing with oil producers



Seed sales - Integrated solution (inc. growth protocol & mechanical harvest)



PIPELINE



Portfolio

1st generation: CR-712

Compact architecture, adapted to mechanical harvest, uniformity, high germination rate

CR-712

2nd generation: CR-103, CR-106

Improved yield, compact architecture, plant type variable

CR-103
CR-106

Pipeline

1st generation: CR -712 Gold

Adaptable to mechanical harvest, Concentrated ripening, Uniformity, High grade oil %

CR-712G

2nd generation: CR -103 Gold, CST-106 Gold

Improved yield, High germination rate, Earliness

CR 103G
CR 106G

3rd generation: CR-128 Gold

Improved yield, Concentrated ripening, Uniformity, Droughty tolerance

CR-128G

4th generation: CR Hybrids

Synergetic & affordable hybrids

CR-1180

Annex II: Financial Fundamentals

KEY FINANCIALS – BALANCE SHEET

Thousand US \$	30.06.2019	31.12.2018
Current Assets	47,795	55,488
Long-Term Assets	5,659	3,206
Total Assets	53,454	58,694
Current Liabilities	4,713	5,431
Long-Term Liabilities	5,883	2,957
Total Shareholders Equity	42,858	50,306
Total Liabilities & Shareholders Equity	53,454	58,694

Key Points:

- Cash position: ~46 million USD as of 30.06.2019
- No debt
- Estimated net cash usage for 2019: \$16-\$18 million
- Listed on TASE (2007) and NASDAQ (2013)

KEY FINANCIALS – P&L

Thousand US \$	H1 2019	H1 2018	Q2 2019	Q2 2018	2018
Revenues	540	745	192	379	1,747
Gross Profit	368	196	91	114	295
Operating Loss	(9,372)	(9,619)	(4,703)	(4,673)	(19,989)
Loss	(7,895)	(10,155)	(4,141)	(4,769)	(20,812)